Tuesday, October 13, 2020 2:44:12 PM
Best part about it all....
Dilution is prohibited...and they have the exclusive rights to patent.
Glad I bought at open
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
“Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.”
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus", and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Dilution is prohibited...and they have the exclusive rights to patent.
Glad I bought at open
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
“Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.”
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus", and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Recent HALB News
- Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University • GlobeNewswire Inc. • 11/03/2025 01:00:00 PM
- Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform • GlobeNewswire Inc. • 10/27/2025 12:00:00 PM
- Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment • GlobeNewswire Inc. • 09/29/2025 12:00:00 PM
